Malvern Instrument?s Announces Guest Presenter for March 18th Protein Characterisation Webinar
Malvern Instruments welcomes Prof. Dr. John F. Carpenter, from the University of Colorado Center for Pharmaceutical Biotechnology, as a guest presenter contributing to the company’s current series of webinars.
Professor Carpenter is a renowned expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations. In his webinar on 18 March 2014 he will discuss how the combination of dynamic light scattering technology with Raman spectroscopy delivers new insights into the measurement and prediction of protein stability, aggregation and high order structure.
The non-invasive and non-destructive determination of numerous physicochemical properties of protein therapeutics and their aggregates is critical for developing formulation conditions that enhance product efficacy, stability and manufacturability. To meet the analytical challenges in early stage development, where the amount of material is limited, tools that measure very small volumes are also highly desirable.
In his webinar presentation, Prof. Carpenter will describe the combination of two established analytical techniques, dynamic light scattering (DLS) and Raman spectroscopy. Together they can be used to derive structural, thermodynamic and kinetic insights into the mechanisms of protein aggregation and the factors that influence protein stability. He will present a number of examples using model systems and manufactured biopharmaceutical products to illustrate the synergies of the two techniques and the new insights afforded by the combined approach.
Looking forward to the webinar, Dr Lisa Newey-Keane, Biopharmaceutical Portfolio Manager for Malvern, said: “We are delighted that Prof. Carpenter has agreed to talk about the work that he has been doing and to describe the use of a combined DLS/Raman Spectroscopy approach to protein characterization. His expertise in protein systems, especially in biopharmaceutical formulations, will provide a highly informative backdrop to the combined application of these two techniques and the examples he plans to describe will put this into the context of solving real-world problems.”
Prof. Dr John F. Carpenter is an expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations, during bioprocessing and in delivery systems. He has published more than 200 peer-reviewed papers and is an inventor on 19 issued patents. He is Editor for Reviews and Commentaries for Journal of Pharmaceutical Sciences and serves on the Editorial Advisory Boards for various pharmaceutical journals.
Webinar registration is free and is open to all as part of Malvern’s continuing programme of information and education. For further details and to register, please visit www.malvern.com/dlsraman
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance